clinical trial · NCT06956170
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
Multiple MyelomaBelantamab mafodotinPomalidomideDexamethasoneBortezomib
brief summary
This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone compared with that of combination of pomalidomide, bortezomib and dexamethasone in Japanese participants with relapsed/refractory multiple myeloma (RRMM).
started
Feb 10, 2022
primary completion
May 27, 2024
completion
Jun 25, 2029
last updated
Jun 12, 2026
official title
A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol